01 / URGENCY
Designed for acute settings
Being developed as a sterile, ready-to-use IV injectable for administration in emergency settings.
PINWHEEL THERAPEUTICS
Reimagining
anticoagulant reversal.
Investigational product
We are advancing ciraparantag, an investigational small molecule designed to address a critical unmet need in anticoagulation care.
Phase 2 clinical development
OUR MISSION
Pursuing rapid anticoagulant reversal for time-critical care.
Pinwheel Therapeutics is developing ciraparantag (PW-977) as a potential treatment for reversal of factor Xa inhibitor anticoagulation in patients with major bleeding when medically indicated.
Our goal is to translate rigorous science into a ready-to-use therapeutic option for clinicians managing time-critical bleeding emergencies.
A FOCUSED APPROACH
Built around the realities of emergency care.
02 / SCIENCE
A proprietary small molecule
Published preclinical studies describe ciraparantag as noncovalently binding factor Xa inhibitors. Ciraparantag is being investigated for reversal of their anticoagulant activity.
03 / EVIDENCE
Published clinical and non-clinical studies
The program is informed by clinical trials and an evolving body of scientific evidence.